查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2102894

抗菌藥物敏感性檢測市場：全球市場預測，2026-2032年

Antimicrobial Susceptibility Testing Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗菌藥物敏感性測試市場將成長至 64.3 億美元，複合年成長率為 6.07%。

主要市場統計數據
基準年 2025 42.5億美元
預計年份：2026年 45億美元
預測年份 2032 64.3億美元
複合年成長率 (%) 6.07%

隨著抗生素抗藥性持續威脅全球患者預後、醫院容量和公共衛生系統，抗菌藥物敏感性檢測正成為現代感染疾病控制的關鍵支柱。此領域涵蓋表現型檢測、自動化分析儀、紙錠擴散法、肉湯微量稀釋法、濃度梯度法、快速抗生素敏感性檢測、分子水平抗藥性檢測以及整合實驗室資訊工作流程。其價值在於指南標靶治療、支持合理使用抗生素方案、減少頻譜抗生素的不合理使用，並為醫院、參考實驗室、公共衛生網路和研究機構中抗藥性病原體的監測提供資訊。多重抗藥性細菌的出現、對敗血症和血流感染疾病管理的日益重視、不斷擴大的感染預防要求以及對更快、標準化且臨床適用結果的需求，都推動了抗菌藥物敏感性檢測的發展。全球衛生機構仍將抗生素抗藥性視為重大的公共衛生威脅，而臨床標準則強調品管的檢測、病原體特異性基準值以及實證解讀。因此，可靠的抗菌藥物敏感性測試對於常規微生物檢測、疫情應對、患者安全和國家級抗藥性監測計劃至關重要。

抗菌藥物敏感性測試領域的變革性變化

抗菌藥物敏感性檢測領域正從傳統的勞動密集型工作流程轉向快速、自動化且數位化連接的平台，以支持早期治療決策。檢查室優先考慮縮短週轉時間、簡化從檢體到結果的流程、提高可追溯性以及與電子健康記錄、實驗室資訊系統和抗菌藥物管理平台的互通性。一項重大變革是將表現型檢測和分子診斷相結合，使檢查室能夠將細菌生長抑制的直接證據與抗藥性基因和機制的快速檢測相結合。另一項變革是監測關聯檢測的作用日益增強，標準化的敏感性數據支持疫情爆發檢測、建構累積抗菌藥物敏感性譜、預防​​感染以及製定抗菌藥物使用政策。臨床檢查室還被要求透過自動化、遠端審核、中間件整合和簡化品管來應對人手不足。同時，隨著閾值的更新和病原體-藥物組合的變化，需要持續的檢驗、人員培訓以及微生物學、藥物警戒、感染疾病和感染預防團隊之間的密切合作。

人工智慧對抗菌藥物敏感性測試的累積影響

人工智慧 (AI) 正在透過改善工作流程分診、影像解讀、結果檢驗、抗藥性模式識別和臨床決策支持，變革抗菌藥物敏感性檢測。 AI 驅動的分析使檢查室能夠識別異常的藥敏譜，精準定位潛在的品質問題，並優先處理關鍵結果，從而支持對高風險感染疾病（例如血流感染疾病、肺炎和複雜性尿道感染）進行快速篩檢。目前，用於從基因組學、蛋白質組學、表現型和歷史實驗室數據預測抗藥性的機器學習模型也正在評估中，但其臨床應用需要嚴格的檢驗、透明度、數據管治以及與監管要求的一致性。當 AI 與微生物專家的解讀相輔相成，而非取代時，其累積影響最為顯著。短期內，AI 的最大價值預計體現在減少人工工作量、加強對合理使用抗菌藥物的建議、幫助深入了解區域抗菌藥物敏感性譜以及加快臨床醫生獲得可操作指導的速度。然而，人工智慧的引入必須解決諸如資料集中的偏見、病原體多樣性、區域抗藥性差異、網路安全以及臨床醫生可以信賴的可靠且可解釋的輸出等挑戰。

全球抗菌藥物敏感性測試的關鍵區域見解

在亞太地區，人口密度高、感染疾病負擔沉重、醫院網路不斷擴張以及各國為應對抗生素抗藥性而製定的行動計劃，正促使人們日益關注抗生素敏感性檢測。該地區各國正增加對檢查室能力、監測和抗生素使用規範的投入，從而導致對集中式參考檢測和三級醫療機構快速診斷的需求不斷成長。北美地區仍然是一個以規範為主導的地區，其抗生素使用要求、先進的醫院檢查室、與電子健康記錄的整合以及公共衛生監測項目，都支持積極採用標準化的敏感性檢測。在拉丁美洲，人們日益關注抗藥性革蘭氏陰性病原體、醫療相關感染以及先進微生物基礎設施取得的差異，這推動了診斷能力的提升，也進一步凸顯了提高檢查室的重要性。在歐洲，已建立的抗生素抗藥性監測系統、嚴格的基準值協調以及廣泛的抗菌藥物管理活動，正促使人們更加重視標準化方法、跨境監測和謹慎使用抗生素。在中東，對醫療基礎設施、三級醫療機構和感染控制能力的投資正在增加，尤其是在醫療系統致力於控制醫院感染和區域性抗生素抗藥性問題之際。在非洲，儘管診斷服務的可及性存在顯著差異，但國際衛生舉措、國家抗生素抗藥性行動計畫以及檢查室網路的建設正在提升藥敏試驗在患者照護和監測中的作用，尤其是在主要都市區以外的地區，這些地區的微生物檢測能力正在不斷增強。

抗菌藥物敏感性試驗引入的關鍵群體分析

在東南亞國協，抗菌藥物敏感性檢測正透過區域抗菌藥物抗藥性合作、檢查室能力建設和醫院合理用藥管理得到推廣；然而，由於基礎設施、保險報銷和人力資源可用性的差異，各成員國的實施情況不盡相同。海灣合作理事會（GCC）國家的特點是醫療保健投入巨大、三級醫療機構不斷擴建，並且日益重視感染預防，這催生了對自動化微生物檢測、快速檢測和可靠的合理用藥管理分析的需求。歐盟受益於強調協調抗菌藥物抗藥性監測、統一檢查室標準以及將人類健康、獸醫用藥、食品系統和環境監測聯繫起來的「同一健康」理念的政策。金磚國家人口眾多，感染疾病負擔沉重，國家醫療保健體係不斷擴展，並且公眾對抗藥性病原體的擔憂日益加劇，因此，它們在抗菌藥物敏感性檢測領域是一個多元化但極具影響力的群體。七國集團（G7）國家普遍擁有成熟的臨床實驗室體系、強力的法律規範、完善的合理使用政策以及先進的數位健康整合應用，使其成為品質、自動化和監測主導檢測的重要標竿。北約成員國（其中許多與已開發的衛生經濟體重疊）在戰略上優先考慮感染疾病防範、應對抗生素抗藥性和可部署的診斷能力，尤其是在軍事醫學、跨境衛生安全和緊急應變領域。

主要國家抗菌藥物敏感性測試的趨勢

在美國，成熟的抗生素敏感性檢測系統已建立，這得益於醫院對合理使用抗生素的要求、先進的檢查室自動化、公共衛生監測以及對快速最佳化治療方案的高度重視。中國正在擴大診斷能力和加強抗生素監管，同時應對巨大的臨床需求、進行抗藥性監測並推動醫院檢查室現代化。德國的特點是擁有先進的檢查室基礎設施、高品質的臨床微生物學實踐，並在醫院和參考實驗室積極採用標準化的敏感性檢測方法。在英國，已建立起強大的抗生素抗藥性應對網路、全國性的監測體系，以及微生物檢查室與抗生素使用計畫之間的密切合作。在日本，先進的醫療基礎設施與審慎的抗生素使用政策和高品質的檢測標準相結合。加拿大在其省級和國家級醫療體系中強調標準化的檢測方法、抗生素使用和監測，並持續關注醫院和社區醫療機構中的抗藥性細菌。義大利和法國保持嚴格的抗生素抗藥性監測和合理使用政策，臨床檢查室支持協調一致的抗生素使用舉措和醫療相關感染控制。印度是抗菌藥物敏感性檢測的關鍵國家，因為其感染疾病負擔沉重，抗藥性問題突出，並且正在擴大國家抗菌藥物抗藥性（AMR）舉措，重點在於合理用藥和加強檢測能力。巴西在拉丁美洲的抗菌藥物抗藥性監測中發揮著至關重要的作用，這得益於其大規模的醫院網路、學術微生物中心以及不斷擴大的合理用藥推廣。俄羅斯在感染疾病和抗菌藥物抗藥性方面面臨複雜的情況，需要實現檢測標準化、監測一致性和提高區域檢測能力。在墨西哥，加強診斷和監測能力的工作正在進行中，控制病菌感染和醫療相關感染仍然是公共衛生工作的首要任務。澳洲擁有完善的國家抗菌藥物抗藥性監測和管理框架，並由發達的檢查室網路提供支援。在西班牙，抗藥性革蘭氏陰性菌仍然是急診護理的一個主要問題，醫療相關感染控制、管理和可靠的藥敏試驗仍然是優先事項。韓國擁有技術先進的醫療保健系統，正在推動快速診斷、院內感染控制和基於監測的抗生素抗藥性管理。

為行業領導者提供的實用建議

產業領導者應優先考慮能夠縮短獲得有效結果時間並同時保持檢驗藥敏試驗嚴謹性的解決方案。策略投資應著重於自動化、快速表現型檢測、分子層級抗藥性檢測、中介軟體連接以及與抗菌藥物風險管理工作流程整合的決策支援工具。產品和服務組合應涵蓋整個實驗室環境，從高通量集中式設施到需要簡化、穩健且品管方法的資源受限環境。領導者必須使其服務與公認的臨床標準、不斷變化的斷點以及當地的抗菌藥物抗藥性流行病學保持一致，同時確保新方法和人工智慧驅動的功能擁有清晰的檢驗數據。與醫院、公共衛生檢查室、學術機構和抗菌藥物風險管理團隊夥伴關係可以增強證據生成並加速有效應用。此外，由於應用障礙通常源於工作流程中斷、人員配備限制和整合複雜性，而非檢測本身的效能，因此各機構也應投資於培訓、技術支援、網路安全和資料互通性。一個穩健的策略應該優先考慮臨床效用、對合理使用抗生素的影響、檢查室效率以及對抗生素抗藥性監測的貢獻，而不是依賴檢驗的說法。

抗菌藥物敏感性試驗的調查方法

本執行摘要基於系統性的二手研究途徑，採用檢驗的公共衛生、臨床、監管和科學二手訊息，這些資訊與抗菌藥物敏感性測試和抗菌藥物抗藥性有關。該調查方法強調世界衛生組織、各國抗菌藥物抗藥性行動計畫、臨床微生物學標準、同行評審文獻、監測計畫結果、合理使用指南和檢查室最佳實踐文件等方面的證據。透過對診斷工作流程、技術採納模式、區域醫療保健系統優先事項和政策促進因素進行主題分析，整合了相關見解。特別注意避免不合理的商業性假設，並排除市場規模估算、市場規模計算、市場佔有率和預測。透過比較已記錄的醫療保健基礎設施趨勢、抗菌藥物抗藥性優先事項、監測成熟度和檢查室能力指標，建構了區域、群體和國家層面的分析。本分析著重於對產業趨勢、技術演進和可操作的採納促進因素進行資料支援的定性解讀，而非推測性的數值預測。

結論

抗菌藥物敏感性檢測在全球應對抗生素抗藥性方面發揮核心作用，它使臨床醫生能夠選擇有效的治療方案，檢查室能夠檢測新出現的抗藥性菌株，醫療系統能夠加強合理用藥和監測。該領域正朝著更快、更自動化、數位化整合的工作流程發展，同時保持檢驗的表現型分析和標準化解讀的臨床重要性。人工智慧、分子診斷和互聯檢查室平台正在提升敏感性檢測的策略價值，但其成功取決於實證部署、品質保證、互通性和訓練有素的微生物學專家。基礎設施、政策成熟度和抗藥性細菌負擔方面的區域差異將繼續影響部署重點，從成熟醫療環境中高度自動化的系統到新興醫療系統中的能力建設和標準化訪問。專注於臨床效用、與合理用藥一致、工作流程效率和監測準備的行業領導企業將更有能力支持不斷變化的感染疾病控制需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：抗菌藥物敏感性測試市場：依產品/服務分類

  • 裝置
    • 自動化系統
    • 手動裝置
  • 試劑和試劑盒
    • 抗菌藥物敏感性測試試劑盒
    • 微生物鑑定試劑盒
  • 服務
    • 分析測試服務
    • 客製化測試解決方案

第8章：抗菌藥物敏感性檢測市場：依檢測類型分類

  • 抗菌藥物敏感性試驗
  • 抗真菌藥物敏感性試驗
  • 抗寄生蟲藥物敏感性試驗
  • 抗病毒藥物敏感性試驗

第9章：抗菌藥物敏感性測試市場：依方法分類

  • 定性方法
    • 瓊脂稀釋法
    • 自動化抗菌藥物敏感性測試（AST）
    • 紙錠擴散法
    • 基因分型
  • 定量方法

第10章：抗菌藥物敏感性測試市場：依應用領域分類

  • 臨床診斷
  • 藥物發現與開發
  • 流行病學

第11章：抗菌藥物敏感性測試市場：以最終用戶分類

  • 學術和政府附屬研究機構
  • 醫院和診斷中心
  • 製藥和生物技術公司

第12章：抗菌藥物敏感性檢測市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：抗菌藥物敏感性測試市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 抗菌藥物敏感性檢測市場：依國家分類

  • 美國
  • 中國
  • 德國
  • 英國
  • 日本
  • 加拿大
  • 義大利
  • 法國
  • 印度
  • 巴西
  • 俄羅斯
  • 墨西哥
  • 澳洲
  • 西班牙
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Accelerate Diagnostics, Inc.
  • ALIFAX SRL
  • Becton, Dickinson and Company
  • BIOANALYSE TIbbi Malz. San. ve Tic. Ltd. Sti.
  • BioMerieux SA
  • Bruker Corporation
  • Creative Diagnostics
  • Danaher Corporation
  • Erba Group
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche AG
  • Himedia Laboratories Private Limited
  • INTEGRA Biosciences AG
  • LABORATORIOS CONDA, SA
  • Leading Biology, Inc.
  • Liofilchem Srl
  • Mast Group Ltd.
  • MP Biomedicals, LLC by Valiant Co. Ltd
  • Qiagen NV
  • QuantaMatrix Inc.
  • Resistell AG
  • Synoptics Ltd.
  • Thermo Fisher Scientific Inc.
  • Zhuhai DL Biotech Co., Ltd.
Product Code: MRR-464C422F4BD3

The Antimicrobial Susceptibility Testing Market is projected to grow by USD 6.43 billion at a CAGR of 6.07% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.25 billion
Estimated Year [2026] USD 4.50 billion
Forecast Year [2032] USD 6.43 billion
CAGR (%) 6.07%

Antimicrobial susceptibility testing is becoming a critical pillar of modern infectious disease management as antimicrobial resistance continues to threaten patient outcomes, hospital capacity, and public health systems worldwide. The discipline spans phenotypic testing, automated instruments, disk diffusion, broth microdilution, gradient methods, rapid antimicrobial susceptibility testing, molecular resistance detection, and integrated laboratory information workflows. Its value lies in guiding targeted therapy, supporting antimicrobial stewardship programs, reducing inappropriate broad-spectrum antibiotic use, and informing surveillance of resistant pathogens across hospitals, reference laboratories, public health networks, and research settings. Demand is being shaped by rising multidrug-resistant organisms, greater focus on sepsis and bloodstream infection management, expanded infection prevention requirements, and the need for faster, standardized, and clinically actionable results. Global health authorities continue to identify antimicrobial resistance as a major public health threat, while clinical standards emphasize quality-controlled testing, organism-specific breakpoints, and evidence-based interpretation. As a result, reliable antimicrobial susceptibility testing is essential for routine microbiology, outbreak response, patient safety, and national resistance monitoring programs.

Transformative Shifts in the Antimicrobial Susceptibility Testing Landscape

The antimicrobial susceptibility testing landscape is shifting from conventional, labor-intensive workflows toward rapid, automated, and digitally connected platforms that support earlier treatment decisions. Laboratories are prioritizing shorter turnaround times, sample-to-answer efficiency, traceability, and interoperability with electronic health records, laboratory information systems, and antimicrobial stewardship dashboards. A major transformation is the convergence of phenotypic testing with molecular diagnostics, enabling laboratories to combine direct evidence of bacterial growth inhibition with rapid detection of resistance genes and mechanisms. Another shift is the growing role of surveillance-linked testing, where standardized susceptibility data support outbreak detection, cumulative antibiogram development, infection prevention, and policy decisions on antibiotic use. Clinical laboratories are also facing pressure to address workforce shortages through automation, remote review, middleware integration, and streamlined quality control. At the same time, evolving breakpoint updates and organism-drug combinations require ongoing validation, staff training, and close coordination between microbiology, pharmacy, infectious disease, and infection prevention teams.

Cumulative Impact of Artificial Intelligence on Antimicrobial Susceptibility Testing

Artificial intelligence is beginning to reshape antimicrobial susceptibility testing by improving workflow triage, image interpretation, result validation, resistance pattern recognition, and clinical decision support. AI-enabled analytics can help laboratories identify unusual susceptibility profiles, flag potential quality issues, prioritize critical results, and support faster review of high-risk infections such as bloodstream infections, pneumonia, and complicated urinary tract infections. Machine learning models are also being evaluated for predicting resistance from genomic, proteomic, phenotypic, and historical laboratory data, although clinical implementation requires rigorous validation, transparency, data governance, and alignment with regulatory expectations. The cumulative impact of artificial intelligence is most meaningful when it augments, rather than replaces, expert microbiology interpretation. Its strongest near-term value is expected in reducing manual workload, strengthening antimicrobial stewardship recommendations, supporting local antibiogram insights, and improving the speed with which clinicians receive actionable guidance. However, AI adoption must address dataset bias, pathogen diversity, regional resistance variability, cybersecurity, and the need for explainable outputs that clinicians can trust.

Key Regional Insights Across Global Antimicrobial Susceptibility Testing

Asia-Pacific is experiencing heightened attention to antimicrobial susceptibility testing due to dense populations, high infectious disease burden, expanding hospital networks, and national action plans addressing antimicrobial resistance. Countries across the region are investing in laboratory strengthening, surveillance, and stewardship, with demand for centralized reference testing and rapid diagnostics in tertiary care settings. North America remains a highly protocol-driven region where antimicrobial stewardship requirements, advanced hospital laboratories, electronic health record integration, and public health surveillance programs support strong adoption of standardized susceptibility testing. Latin America is strengthening diagnostic capacity amid concerns over resistant Gram-negative pathogens, healthcare-associated infections, and uneven access to advanced microbiology infrastructure, making laboratory quality improvement and regional surveillance increasingly important. Europe benefits from established antimicrobial resistance monitoring systems, strong breakpoint harmonization, and widespread stewardship activity, with an emphasis on standardized methods, cross-border surveillance, and prudent antibiotic use. The Middle East is seeing increased investment in healthcare infrastructure, tertiary hospitals, and infection control capabilities, particularly as healthcare systems focus on hospital-acquired infections and regional antimicrobial resistance containment. Africa faces substantial diagnostic access gaps, but international health initiatives, national AMR action plans, and laboratory network development are improving the role of susceptibility testing in patient care and surveillance, especially where microbiology capacity is being expanded beyond major urban centers.

Key Group Insights for Antimicrobial Susceptibility Testing Adoption

ASEAN countries are advancing antimicrobial susceptibility testing through regional cooperation on antimicrobial resistance, laboratory capacity building, and hospital-based stewardship, although differences in infrastructure, reimbursement, and workforce availability shape adoption across member states. The GCC is characterized by high healthcare investment, expanding tertiary care facilities, and increasing emphasis on infection prevention, creating demand for automated microbiology, rapid testing, and robust stewardship analytics. The European Union benefits from coordinated AMR surveillance, harmonized laboratory standards, and policy emphasis on One Health approaches that connect human health, veterinary use, food systems, and environmental monitoring. BRICS countries represent a diverse but highly influential group in antimicrobial susceptibility testing because they combine large populations, substantial infectious disease burdens, growing domestic healthcare capacity, and increasing public health focus on resistant pathogens. G7 countries generally have mature clinical laboratory systems, strong regulatory oversight, established stewardship policies, and advanced adoption of digital health integration, making them important benchmarks for quality, automation, and surveillance-driven testing. NATO member countries, many of which overlap with advanced healthcare economies, also place strategic importance on infectious disease preparedness, antimicrobial resistance resilience, and deployable diagnostic capacity, particularly in the context of military medicine, cross-border health security, and emergency response.

Key Country Insights in Antimicrobial Susceptibility Testing

The United States has a mature antimicrobial susceptibility testing environment supported by hospital stewardship requirements, advanced laboratory automation, public health surveillance, and high clinical emphasis on rapid treatment optimization. China is expanding diagnostic capacity and stewardship oversight while addressing high-volume clinical demand, resistance surveillance, and hospital laboratory modernization. Germany demonstrates advanced laboratory infrastructure, high-quality clinical microbiology practices, and strong adoption of standardized susceptibility testing in hospital and reference settings. The United Kingdom has well-established antimicrobial resistance strategies, national surveillance, and strong integration between microbiology laboratories and stewardship programs. Japan combines advanced healthcare infrastructure with careful antimicrobial stewardship policies and high-quality laboratory standards. Canada emphasizes standardized laboratory practices, stewardship, and surveillance across provincial and national health systems, with continued focus on resistant organisms in hospitals and community care. Italy and France maintain strong AMR surveillance and stewardship policies, with clinical laboratories supporting coordinated antibiotic use initiatives and healthcare-associated infection control. India is a critical country for antimicrobial susceptibility testing due to its large infectious disease burden, documented resistance challenges, and expanding national AMR initiatives focused on stewardship and laboratory strengthening. Brazil plays a significant role in Latin American antimicrobial resistance monitoring, supported by large hospital networks, academic microbiology centers, and growing stewardship implementation. Russia faces a complex infectious disease and antimicrobial resistance landscape, with demand for improved standardized testing, surveillance consistency, and regional laboratory capacity. Mexico is strengthening diagnostic and surveillance capacity as resistant bacterial infections and healthcare-associated infection control remain public health priorities. Australia has strong national AMR surveillance and stewardship frameworks, supported by well-developed laboratory networks. Spain continues to prioritize healthcare-associated infection control, stewardship, and reliable susceptibility testing as resistant Gram-negative pathogens remain a major concern in acute care. South Korea is advancing rapid diagnostics, hospital infection control, and surveillance-driven antimicrobial resistance management within a technologically advanced healthcare system.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize solutions that reduce time to actionable results while maintaining the rigor of validated susceptibility interpretation. Strategic investments should focus on automation, rapid phenotypic testing, molecular resistance detection, middleware connectivity, and decision-support tools that integrate with stewardship workflows. Product and service portfolios should address the full laboratory continuum, from high-throughput centralized facilities to resource-limited settings requiring simplified, robust, and quality-controlled methods. Leaders should align offerings with recognized clinical standards, evolving breakpoints, and local resistance epidemiology, while ensuring clear validation data for new methods and AI-enabled features. Partnerships with hospitals, public health laboratories, academic centers, and stewardship teams can strengthen evidence generation and accelerate practical adoption. Organizations should also invest in training, technical support, cybersecurity, and data interoperability, as adoption barriers often arise from workflow disruption, workforce limitations, and integration complexity rather than test performance alone. A strong strategy should emphasize clinical utility, stewardship impact, laboratory efficiency, and contribution to antimicrobial resistance surveillance without relying on unverified claims.

Research Methodology for Antimicrobial Susceptibility Testing Insights

This executive summary is built on a structured secondary research approach using verified public health, clinical, regulatory, and scientific sources relevant to antimicrobial susceptibility testing and antimicrobial resistance. The methodology emphasizes evidence from international health agencies, national AMR action plans, clinical microbiology standards, peer-reviewed literature, surveillance program outputs, stewardship guidelines, and laboratory best-practice documentation. Insights were synthesized through thematic analysis of diagnostic workflows, technology adoption patterns, regional health system priorities, and policy drivers. Particular attention was given to avoiding unsupported commercial assumptions and excluding market estimation, market sizing, market share, and forecasting. Regional, group, and country narratives were developed by comparing documented healthcare infrastructure trends, antimicrobial resistance priorities, surveillance maturity, and laboratory capacity indicators. The analysis focuses on qualitative, data-backed interpretation of industry dynamics, technology shifts, and practical adoption factors rather than speculative numerical projections.

Conclusion

Antimicrobial susceptibility testing is central to the global response against antimicrobial resistance, enabling clinicians to select effective therapy, laboratories to detect emerging resistance, and health systems to strengthen stewardship and surveillance. The field is moving toward faster, more automated, and digitally integrated workflows while retaining the clinical importance of validated phenotypic methods and standardized interpretation. Artificial intelligence, molecular diagnostics, and connected laboratory platforms are expanding the strategic value of susceptibility testing, but success depends on evidence-based implementation, quality assurance, interoperability, and trained microbiology expertise. Regional differences in infrastructure, policy maturity, and resistance burden will continue to shape adoption priorities, from advanced automated systems in mature healthcare settings to capacity-building and standardized access in emerging health systems. Industry leaders that focus on clinical utility, stewardship alignment, workflow efficiency, and surveillance readiness will be best positioned to support the evolving needs of infectious disease management.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Antimicrobial Susceptibility Testing Market, by Offerings

  • 7.1. Introduction
  • 7.2. Instruments
    • 7.2.1. Automated Systems
    • 7.2.2. Manual Instruments
  • 7.3. Reagents & Kits
    • 7.3.1. Antibiotic Susceptibility Kits
    • 7.3.2. Microbial Identification Kits
  • 7.4. Services
    • 7.4.1. Analytical Testing Services
    • 7.4.2. Custom Testing Solutions

8. Antimicrobial Susceptibility Testing Market, by Test Type

  • 8.1. Introduction
  • 8.2. Antibacterial Susceptibility Testing
  • 8.3. Antifungal Susceptibility Testing
  • 8.4. Antiparasitic Susceptibility Testing
  • 8.5. Antiviral Susceptibility Testing

9. Antimicrobial Susceptibility Testing Market, by Method

  • 9.1. Introduction
  • 9.2. Qualitative Methods
    • 9.2.1. Agar Dilution
    • 9.2.2. Automated AST
    • 9.2.3. Disk Diffusion
    • 9.2.4. Genotypic Method
  • 9.3. Quantitative Methods

10. Antimicrobial Susceptibility Testing Market, by Application

  • 10.1. Introduction
  • 10.2. Clinical Diagnostics
  • 10.3. Drug Discovery & Development
  • 10.4. Epidemiology

11. Antimicrobial Susceptibility Testing Market, by End User

  • 11.1. Introduction
  • 11.2. Academic & Government Research Institutes
  • 11.3. Hospitals & Diagnostic Centers
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Antimicrobial Susceptibility Testing Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Antimicrobial Susceptibility Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Antimicrobial Susceptibility Testing Market, by Country

  • 14.1. United States
  • 14.2. China
  • 14.3. Germany
  • 14.4. United Kingdom
  • 14.5. Japan
  • 14.6. Canada
  • 14.7. Italy
  • 14.8. France
  • 14.9. India
  • 14.10. Brazil
  • 14.11. Russia
  • 14.12. Mexico
  • 14.13. Australia
  • 14.14. Spain
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Accelerate Diagnostics, Inc.
  • 16.2. ALIFAX S.R.L
  • 16.3. Becton, Dickinson, and Company
  • 16.4. BIOANALYSE TIbbi Malz. San. ve Tic. Ltd. Sti.
  • 16.5. BioMerieux SA
  • 16.6. Bruker Corporation
  • 16.7. Creative Diagnostics
  • 16.8. Danaher Corporation
  • 16.9. Erba Group
  • 16.10. Eurofins Scientific SE
  • 16.11. F. Hoffmann-La Roche AG
  • 16.12. Himedia Laboratories Private Limited
  • 16.13. INTEGRA Biosciences AG
  • 16.14. LABORATORIOS CONDA, S.A.
  • 16.15. Leading Biology, Inc.
  • 16.16. Liofilchem S.r.l.
  • 16.17. Mast Group Ltd.
  • 16.18. MP Biomedicals, LLC by Valiant Co. Ltd
  • 16.19. Qiagen N.V.
  • 16.20. QuantaMatrix Inc.
  • 16.21. Resistell AG
  • 16.22. Synoptics Ltd.
  • 16.23. Thermo Fisher Scientific Inc.
  • 16.24. Zhuhai DL Biotech Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AUTOMATED SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AUTOMATED SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AUTOMATED SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MANUAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MANUAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MANUAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL REAGENTS & KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL REAGENTS & KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBIOTIC SUSCEPTIBILITY KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBIOTIC SUSCEPTIBILITY KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBIOTIC SUSCEPTIBILITY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MICROBIAL IDENTIFICATION KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MICROBIAL IDENTIFICATION KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MICROBIAL IDENTIFICATION KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANALYTICAL TESTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANALYTICAL TESTING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANALYTICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CUSTOM TESTING SOLUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CUSTOM TESTING SOLUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CUSTOM TESTING SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBACTERIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIBACTERIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIBACTERIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIFUNGAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIFUNGAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIFUNGAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIPARASITIC SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIPARASITIC SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIPARASITIC SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIVIRAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIVIRAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIVIRAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL QUALITATIVE METHODS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL QUALITATIVE METHODS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL QUALITATIVE METHODS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AGAR DILUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AGAR DILUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AGAR DILUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AUTOMATED AST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AUTOMATED AST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AUTOMATED AST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DISK DIFFUSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DISK DIFFUSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DISK DIFFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENOTYPIC METHOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENOTYPIC METHOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENOTYPIC METHOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL QUANTITATIVE METHODS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL QUANTITATIVE METHODS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL QUANTITATIVE METHODS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL EPIDEMIOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL EPIDEMIOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL EPIDEMIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ACADEMIC & GOVERNMENT RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ACADEMIC & GOVERNMENT RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ACADEMIC & GOVERNMENT RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HOSPITALS & DIAGNOSTIC CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HOSPITALS & DIAGNOSTIC CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HOSPITALS & DIAGNOSTIC CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 157. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 158. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 159. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 160. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 162. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 163. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 187. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 188. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 189. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 190. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 192. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 193. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 197. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 198. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 199. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 200. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 202. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 203. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. GERMANY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. GERMANY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 228. GERMANY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 229. GERMANY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 230. GERMANY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 231. GERMANY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. GERMANY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 233. GERMANY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 234. GERMANY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. GERMANY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED KINGDOM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED KINGDOM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED KINGDOM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED KINGDOM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED KINGDOM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED KINGDOM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED KINGDOM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED KINGDOM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED KINGDOM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 248. JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 249. JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 250. JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 251. JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 253. JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 254. JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 258. CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 259. CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 260. CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 261. CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 263. CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 264. CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 265. CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. ITALY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 267. ITALY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 268. ITALY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 269. ITALY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 270. ITALY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 271. ITALY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. ITALY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 273. ITALY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 274. ITALY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 275. ITALY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. FRANCE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 277. FRANCE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 278. FRANCE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 279. FRANCE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 280. FRANCE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 281. FRANCE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. FRANCE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 283. FRANCE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 284. FRANCE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 285. FRANCE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 288. INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 289. INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 290. INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 291. INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 293. INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 294. INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 295. INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 298. BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 299. BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 300. BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 301. BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 303. BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 304. BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 305. BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 306. RUSSIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 307. RUSSIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 308. RUSSIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 309. RUSSIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 310. RUSSIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 311. RUSSIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. RUSSIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 313. RUSSIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 314. RUSSIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 315. RUSSIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 316. MEXICO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. MEXICO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 318. MEXICO AN